These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12622767)

  • 21. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
    Appel-Dingemanse S
    Clin Pharmacokinet; 2002; 41(13):1021-42. PubMed ID: 12403641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.
    Novick J; Miner P; Krause R; Glebas K; Bliesath H; Ligozio G; Rüegg P; Lefkowitz M
    Aliment Pharmacol Ther; 2002 Nov; 16(11):1877-88. PubMed ID: 12390096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antinociceptive property of tegaserod in a rat model of chronic visceral hypersensitivity.
    Liang LX; Zhang Q; Qian W; Hou XH
    Chin J Dig Dis; 2005; 6(1):21-5. PubMed ID: 15667554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
    Morganroth J; Rüegg PC; Dunger-Baldauf C; Appel-Dingemanse S; Bliesath H; Lefkowitz M
    Am J Gastroenterol; 2002 Sep; 97(9):2321-7. PubMed ID: 12358251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.
    Hasler WL; Schoenfeld P
    Drug Saf; 2004; 27(9):619-31. PubMed ID: 15230644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans.
    Coffin B; Bouhassira D; Chollet R; Fraitag B; De Meynard C; Geneve J; Lemann M; Willer JC; Jian R
    Aliment Pharmacol Ther; 1996 Dec; 10(6):919-25. PubMed ID: 8971289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome.
    Houghton LA; Fell C; Whorwell PJ; Jones I; Sudworth DP; Gale JD
    Gut; 2007 Sep; 56(9):1218-25. PubMed ID: 17446306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefit-risk assessment of tegaserod in irritable bowel syndrome.
    Lea R; Whorwell PJ
    Drug Saf; 2004; 27(4):229-42. PubMed ID: 15003035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome.
    Delvaux M; Beck A; Jacob J; Bouzamondo H; Weber FT; Frexinos J
    Aliment Pharmacol Ther; 2004 Jul; 20(2):237-46. PubMed ID: 15233705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
    Fidelholtz J; Smith W; Rawls J; Shi Y; Zack A; Rüegg P; Lefkowitz M
    Am J Gastroenterol; 2002 May; 97(5):1176-81. PubMed ID: 12014724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised double-blind placebo-controlled trial of lidamidine HCL in irritable bowel syndrome.
    Awad RA; Llorens F; Camelo AL; Sánchez M
    Acta Gastroenterol Latinoam; 2000; 30(3):169-75. PubMed ID: 10975022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
    Tegaserod Clinical Research Group
    Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stimulation of the nitric oxide-guanosine 3', 5'-cyclic monophosphate pathway by sildenafil: effect on rectal muscle tone, distensibility, and perception in health and in irritable bowel syndrome.
    Fritz E; Hammer J; Schmidt B; Eherer AJ; Hammer HF
    Am J Gastroenterol; 2003 Oct; 98(10):2253-60. PubMed ID: 14572576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers.
    Talley NJ; Camilleri M; Burton D; Thomforde G; Koch K; Rucker MJ; Peterson J; Zinsmeister AR; Earnest DL
    Aliment Pharmacol Ther; 2006 Sep; 24(5):859-67. PubMed ID: 16918891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perceptual sensitivity and response bias during rectal distension in patients with irritable bowel syndrome.
    Corsetti M; Ogliari C; Marino B; Basilisco G
    Neurogastroenterol Motil; 2005 Aug; 17(4):541-7. PubMed ID: 16078943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Desensitization of the peristaltic reflex induced by mucosal stimulation with the selective 5-HT4 agonist tegaserod.
    Grider JR
    Am J Physiol Gastrointest Liver Physiol; 2006 Feb; 290(2):G319-27. PubMed ID: 16223945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of naloxone on rectal sensorimotor function in health.
    Geeraerts B; Van Oudenhove L; Vos R; Karamanolis G; Tack J
    Neurogastroenterol Motil; 2009 Jun; 21(6):639-43, e26. PubMed ID: 19222764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo.
    Beattie DT; Smith JA; Marquess D; Vickery RG; Armstrong SR; Pulido-Rios T; McCullough JL; Sandlund C; Richardson C; Mai N; Humphrey PP
    Br J Pharmacol; 2004 Nov; 143(5):549-60. PubMed ID: 15466450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study.
    Kamm MA; Müller-Lissner S; Talley NJ; Tack J; Boeckxstaens G; Minushkin ON; Kalinin A; Dzieniszewski J; Haeck P; Fordham F; Hugot-Cournez S; Nault B
    Am J Gastroenterol; 2005 Feb; 100(2):362-72. PubMed ID: 15667494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.